Incyte INCY Europe and Japan — Total revenues
Discontinued — last reported Q4 '23
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Incyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Incyte’s 10-K, filed February 13, 2024, on SEC EDGAR. View the filing →
Ask your AI about Incyte's europe and japan — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Incyte's europe and japan — total revenues?
- Incyte (INCY) reported europe and japan — total revenues of $44.83M in Q4 2023.
- What does europe and japan — total revenues mean?
- The total amount of money earned from product sales and licensing in the European and Japanese markets.
- How do you interpret europe and japan — total revenues?
- An increase indicates successful market adoption, effective commercial execution, or favorable pricing dynamics in these regions, while a decrease may signal competitive pressure, regulatory hurdles, or patent expirations.
- How does europe and japan — total revenues compare across companies?
- Comparable to international segment revenue reporting for other mid-to-large cap biopharmaceutical companies, often benchmarked against regional growth rates and local market share in oncology.